Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Aroplatin in Subjects With Recurrent, Unresectable and Metastatic Colorectal Cancer Refractory to 5-Fluorouracil (5-FU)/Leucovorin or Capecitabine, and Irinotecan

NCT00043199 is registered in ClinicalTrials.gov with Aronex Pharmaceuticals as lead sponsor.

NCT NCT00043199
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00043199 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Aroplatin in Subjects With Recurrent, Unresectable and Metastatic Colorectal Cancer Refractory to 5-Fluorouracil (5-FU)/Leucovorin or Capecitabine, and Irinotecan
Lead sponsor
Aronex Pharmaceuticals
Phase
Phase 2
Overall status
Unknown status
Start date
Not reported
Completion date
Not reported
Enrollment
40
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal neoplasms